gastric
mucos
injuri
report
occur
first
h
hospit
admiss
intensivecar
unit
icu
patient
upper
gastrointestin
tract
bleed
ugib
result
stressulcer
common
outcom
injuri
estim
incid
ugib
rang
icu
patient
although
stressulc
prophylaxi
indic
critic
patient
high
risk
ugib
use
drug
increas
likelihood
ventilatorassoci
pneumonia
vap
increas
gastric
bacteri
colonis
gastric
reflux
subsequ
microaspir
lower
respiratori
tract
despit
progress
area
major
issu
relat
manag
vap
risk
factor
remain
unresolv
clinic
practic
stressulc
prophylaxi
prevent
ugib
includ
use
antireflux
agent
sucralf
proton
pump
inhibitor
ppi
pantoprazol
antagonist
ranitidin
sucralf
cover
gastric
mucosa
prevent
movement
bacteria
toward
pharynx
lung
consid
gastric
acid
product
inhibit
use
sucralf
patient
receiv
sucralf
therapi
less
like
experi
aspir
pneumonia
rel
agent
although
risk
aspir
vap
reduc
follow
use
sucralf
develop
ugib
rel
higher
moder
high
qualiti
evid
support
use
acidinhibit
agent
sucralf
prevent
ugib
howev
administr
ppi
acid
inhibitor
facilit
colonis
bacteria
stomach
inhibit
secret
gastric
acid
creat
sourc
bacteri
microaspir
lung
increas
risk
vap
given
increas
risk
pneumonia
andor
ugib
aforement
medic
need
appropri
adjuv
agent
reduc
risk
vap
ugib
concomitantli
minim
complic
glycyrrhiza
glabra
l
licoric
mayb
one
agent
glycyrrhiza
glabra
tradit
medicin
herb
grow
mani
part
world
glycyrrhizin
glycyrrhizin
acid
glabridin
glabren
glabrol
licoflavonol
glycyrol
licoricon
compound
isol
g
glabra
medicin
g
glabra
root
commonli
use
treat
gastric
duoden
ulcer
altern
bismuth
root
shown
protect
role
acid
pepsin
secret
cover
site
lesion
promot
mucou
secret
szweda
et
al
evalu
mucoprotect
effect
g
glabra
ie
liquid
alcohol
extract
canin
colon
mucosa
follow
administr
nsaid
oral
dose
mg
everi
h
dog
weigh
kg
result
show
reduct
sever
nsaidinduc
mucos
damag
prophylact
treatment
g
glabra
sancar
et
al
achiev
result
moreov
ligha
et
al
demonstr
g
glabra
protect
effect
alcoholinduc
gastric
mucosa
damag
increas
mucu
product
prevent
mucu
deplet
andor
inhibit
lipid
peroxid
glycyrrhiza
glabra
thu
offer
natur
approach
manag
gastrooesophag
reflux
diseas
relat
disord
best
knowledg
preclin
clinic
studi
evalu
antireflux
properti
g
glabra
extract
antibacteri
activ
g
glabra
well
known
howev
sever
vitro
studi
shown
mani
compound
isol
extract
g
glabra
antibacteri
effect
methicillin
sensit
staphylococcu
aureu
mssa
methicillin
resist
aureu
mrsa
mycobacterium
tuberculosi
helicobact
pylori
anim
studi
also
reveal
decreas
mortal
viral
activ
use
g
glabra
herp
simplex
sever
acut
respiratori
syndrom
sar
relat
coronaviru
sarscov
respiratori
syncyti
viru
rsv
arbovirus
vesicular
stomat
viru
vsv
influenza
viru
pneumonia
fact
encourag
reader
air
view
comment
complementarymedicin
relat
topic
letter
word
address
editori
offic
consid
select
digest
tract
decontamin
sdd
import
measur
vap
prevent
icu
patient
antimicrobi
properti
g
glabra
might
benefici
reduc
risk
vap
critic
ill
patient
recent
invitro
studi
demonstr
g
glabra
provid
high
grade
protect
alphahaemolysinmedi
alveolar
epitheli
cell
injuri
reliev
pulmonari
inflammatori
reaction
caus
aureusinduc
pneumonia
murin
model
author
propos
g
glabra
may
potenti
use
treatment
aureusinduc
pneumonia
use
combin
betalactam
antibiot
summari
seem
g
glabra
might
reduc
risk
ugib
also
prevent
develop
vap
antibacteri
antireflux
antipept
ulcer
antiinflammatori
effect
icu
intub
patient
furthermor
g
glabra
lowcost
high
toler
minim
sideeffect
recommend
invitro
research
field
also
respect
efficaci
g
glabra
relat
compound
adjuv
therapi
clinic
medicin
yet
proven
thu
suggest
doubleblind
randomis
control
studi
g
glabra
appropri
dosag
durat
treatment
conduct
patient
undergo
mechan
ventil
icu
close
monitor
vap
ugib
occurr
